News | Optical Coherence Tomography (OCT) | May 16, 2016

OCT Helps Predict Significant Side Branch Ostium Stenosis

Optical Coherence Tomography Bifurcation Study (ORBID) identified predictors in SCAI late-breaker

OCT, ORBID study

May 16, 2016 — In a new study using optical coherence tomography (OCT), an invasive laser imaging technique that provides high-resolution images, researchers found that maximum lipid arc and the presence of lipid plaque contralateral to the side branch (SB) ostium before stenting may contribute to significant side branch ostium stenosis (SBOS) after stenting. The results of the ORBID study were presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting.

Stenting in the main vessel can result in significant SBOS, making it important for interventional cardiologists to be able to identify at-risk patients before they undergo percutaneous coronary intervention (PCI). Significant SBOS is defined as a blockage of 50 percent or more based on angiography. ORBID study researchers aimed to identify predictors of significant SBOS before a stent is introduced in the main vessel, using OCT, which is in the research-phase for this application. OCT is more accurate and provides higher resolution imaging than ultrasound, which is currently the most widely used method in clinical care.

“When inserting a stent into the main vessel of a patient, we have the option of also inserting a wire in the side branch in case SBOS occurs,” said Samin Sharma, M.D., FSCAI, an investigator of the study and director of clinical cardiology and intervention, dean of international clinical affiliations, and president of the Mount Sinai Heart Network, The Mount Sinai Hospital, N.Y. “In our study, OCT proved helpful in identifying predictors of SBOS prior to PCI, which may allow for avoiding inserting a wire in the side branch in select cases.”

The prospective single-center study analyzed 30 patients who did not have initial blockage in the SB ostium. Post-stenting significant SBOS was observed in 30 percent of patients. Affected patients were characterized by a higher prevalence of lipids in the blood (100 vs. 64 percent, p = 0.040) and spotty calcifications (60 vs. 0 percent, p = 0.005).

A multivariate logistic regression analysis identified maximal lipid arc (odds ratio [OR]: 1.014, p = 0.038) and the presence of lipid plaque contralateral to SB ostium (OR: 8.14, p = 0.046) before stenting as independent predictors of significant SBOS.
“This initial study indicates that OCT is a helpful tool in identifying predictors of significant SBOS in patients before they receive a stent,” Sharma said. “In the future, this imaging technology could be broadly introduced as a tool to identify at-risk patients, thereby giving interventional cardiologists more information before doing bifurcation stenting.”

Sharma reported no disclosures. The study was sponsored by Boston Scientific.

For more information: www. SCAI.org/SCAI2016 

 

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now